In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|January 27, 2023
To Meet Updated FDA Recommendations, Novavax Will Update Protein-Based COVID-19 Vaccine
Author(s)Nina Cosdon
Novavax will update its protein-based COVID-19 vaccine, but maintains the current vaccine is effective against current and future variants.
Advertisement
Yesterday, the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC)
The advisory committee’s 21-0 vote to unify vaccine doses means we will likely move away from monovalent COVID-19 vaccines, making
During the VRBPAC meeting, preeminent COVID-19 vaccine developers
The only approved bivalent booster shots, mRNA vaccines from Pfizer-BioNTech and Moderna, contain strains from both the ancestral Wuhan virus and Omicron BA.4/BA.5. The Centers for Disease Control and Prevention
This morning, Novavax
“Novavax is prepared to deliver an updated vaccine following FDA guidance on strain change,” said Silvia Taylor, executive vice president and chief communications officer of Novavax.
At the same time, Novavax argued that their existing protein-based COVID-19 vaccine, NVX-CoV2373, induces a broad immune response against current and genetic drift variant.
“Offering vaccine choices—and ensuring continuous access to those choices—must be at the center of any strategy to protect public health against COVID-19,” Taylor emphasized. “As expressed by several VRBPAC members, the Novavax protein-based COVID-19 vaccine plays an important role in protecting public health as part of a diverse portfolio.”
Advertisement
Related to this article
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
Detection of the virulent neurotropic fungus Cladophialophora bantiana in clinical samples, primarily CNS tissue, increased four-fold in the period from 2023 to 2025.
Advertisement
Advertisement